Literature Review

In the future, tissue engineering, the reconstruction of organs or organ parts, will produce further and better approaches for the treatment of diseases in widely differing fields. Marred cells or cell structures are thereby renewed so that organs are able to again carry out their original function. One of the next steps will be the growth of whole organs and organ parts. 

 

Possible and Future Fields of Application

TICEBA BlueMan - Future Fields of Application

Stroke:
Replacement of defective neuronal tissue

Alzheimer's or Parkinson's Disease:
Reproduction of neuronal cells

Multiple Sclerosis:
Replacement of damaged neuronal cells

Heart Attack:
Renewal of damaged heart muscle cells

Cardiac Insufficiency:
Renewal of insufficient heart muscle tissue

Anti-Aging:
Overall regeneration

Muscle Dystrophies:
Regeneration and build-up of musculature

Paraplegia:
Renewal of neural channels

TICEBA - Stem Cells - Possible and Future Fields of Application

 

  • Stroke: Replacement of defective neuronal tissue
  • Heart Attack: Renewal of damaged heart muscle cells
  • Cardiac Insufficiency: Renewal of insufficient heart muscle tissue
  • Alzheimer's or Parkinson's Disease: Reproduction of neuronal cells
  • Muscle Dystrophies: Regeneration and build-up of musculature
  • Paraplegia: Renewal of neural channels
  • Multiple Sclerosis: Replacement of damaged neuronal cells
  • Anti-Aging: Overall regeneration


The described treatments are only a small insight into the diverse future application possibilities of stem cells due to tissue engineering.

Moreover RHEACELL is developing specific drugs based on mesenchymal skin stem cells for the treatment of various diseases.

News
Clinical Trials

We are now also recruiting patients for further clinical studies in phase I/IIa with allogeneic ABCB5-positive (ABCB5+) mesenchymal stem cells for the following indications: chronic venous ulcer (CVU), diabetic foot ulcer (DFU) and peripheral arterial occlusive disease (PAOD). For more information click HERE.

License

Besides the authorization to manufacture a human medicinal product in accordance with § 13 (1) of the German Medicinal Products Act (AMG) for autologous mesenchymal stem cells, TICEBA is also authorized to manufacture a medicinal product for allogeneic mesenchymal as well as allogeneic limbal ABCB5 + stem cells following a recent extension. For more information click HERE.

The Story of Stem Cells

Review our category "The Story of Stem Cells" with the newest topic "Stem cells in wound healing" HERE.

Newsletter